Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Three-day IV fosaprepitant safety study in pediatric chemotherapy-induced nausea and vomiting
NL-OMON48224Phase 4Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of fosaprepitant, sponsored by Merck & Co. Started Dec 2019; status: active, not recruiting.
02
Drugs
fosaprepitant
Beyond the preview
Go deeper on NL-OMON48224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48224.